• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

趋化因子受体 7（CCR7）（+）T 淋巴细胞浸润肿瘤是转移性结直肠癌的有利预后因素。

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer.

机构信息

Medical Oncology Unit; Oncology Department; Azienda Ospedaliera Universitaria Senese; Siena, Italy.

出版信息

Oncoimmunology. 2012 Jul 1;1(4):531-532. doi: 10.4161/onci.19404.

DOI:10.4161/onci.19404
PMID:22754775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3382880/
Abstract

The immune interactions occurring within the tumor microenvironment have a critical role in determining the outcome of colorectal cancer patients. We carried-out an immunohistochemical analysis of tumor infiltrating T-lymphocytes expressing chemokine receptor 7 (CCR7) in a series of colorectal cancer patients enrolled in a prospective clinical trial. We demonstrated that a high tumor infiltration score of this lymphocyte subset is predictive of longer progression free survival and overall survival.

摘要

肿瘤微环境中发生的免疫相互作用在决定结直肠癌患者的结局方面起着关键作用。我们对参加前瞻性临床试验的一系列结直肠癌患者的肿瘤浸润 T 淋巴细胞表达趋化因子受体 7（CCR7）进行了免疫组织化学分析。我们证明，这种淋巴细胞亚群的高肿瘤浸润评分可预测更长的无进展生存期和总生存期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01a5/3382880/57f26db75d00/onci-1-531-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01a5/3382880/57f26db75d00/onci-1-531-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01a5/3382880/57f26db75d00/onci-1-531-g1.jpg

相似文献

1
Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer.趋化因子受体 7（CCR7）（+）T 淋巴细胞浸润肿瘤是转移性结直肠癌的有利预后因素。
Oncoimmunology. 2012 Jul 1;1(4):531-532. doi: 10.4161/onci.19404.
2
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.T 淋巴细胞表达趋化因子受体 7（CCR7）浸润肿瘤可预测晚期结直肠癌患者的良好预后。
Clin Cancer Res. 2012 Feb 1;18(3):850-7. doi: 10.1158/1078-0432.CCR-10-3186. Epub 2011 Dec 5.
3
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.表达FoxP3、CCR7或PD-1的肿瘤浸润性T淋巴细胞可预测生化复发后接受挽救性放疗的前列腺癌患者的预后。
Cancer Biol Ther. 2016 Nov;17(11):1213-1220. doi: 10.1080/15384047.2016.1235666.
4
Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.促炎趋化因子-趋化因子受体相互作用在尤文肉瘤微环境中决定 CD8(+) T 淋巴细胞浸润并影响肿瘤进展。
J Pathol. 2011 Feb;223(3):347-57. doi: 10.1002/path.2819. Epub 2010 Dec 10.
5
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.肿瘤浸润淋巴细胞：结直肠癌患者生存的有趣参与者。
BMC Immunol. 2010 Apr 12;11:19. doi: 10.1186/1471-2172-11-19.
6
The prognostic significance and relationship with body composition of CCR7-positive cells in colorectal cancer.结直肠癌中CCR7阳性细胞的预后意义及其与身体组成的关系。
J Surg Oncol. 2015 Jul;112(1):86-92. doi: 10.1002/jso.23959. Epub 2015 Jul 14.
7
Increased tumor-infiltrating CD45RACCR7 regulatory T-cell subset with immunosuppressive properties foster gastric cancer progress.具有免疫抑制特性的肿瘤浸润性CD45RACCR7调节性T细胞亚群增加促进胃癌进展。
Cell Death Dis. 2017 Aug 17;8(8):e3002. doi: 10.1038/cddis.2017.388.
8
Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.与结直肠癌中细胞毒性淋巴细胞浸润和存活相关的免疫基因组途径。
BMC Cancer. 2020 Feb 14;20(1):124. doi: 10.1186/s12885-020-6513-4.
9
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.趋化因子驱动的淋巴细胞浸润：决定可切除肝细胞癌长期生存的早期肿瘤内事件。
Gut. 2012 Mar;61(3):427-38. doi: 10.1136/gutjnl-2011-300509. Epub 2011 Sep 19.
10
Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile.结直肠癌浸润 T 淋巴细胞表现出独特的趋化因子受体表达谱。
Eur J Med Res. 2017 Oct 11;22(1):40. doi: 10.1186/s40001-017-0283-8.

引用本文的文献

1
Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer.调节性T细胞的瘤内密度是结直肠癌宿主免疫反应和化疗反应的一个预测指标。
Am J Cancer Res. 2022 Feb 15;12(2):490-503. eCollection 2022.
2
The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.FoxP3+ 肿瘤浸润淋巴细胞对直肠癌的预后价值取决于 CD8+ 细胞毒性 T 细胞密度定义的免疫表型。
Front Immunol. 2022 Jan 24;13:781222. doi: 10.3389/fimmu.2022.781222. eCollection 2022.
3
Combination strategies to maximize the benefits of cancer immunotherapy.

本文引用的文献

1
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.T 淋巴细胞表达趋化因子受体 7（CCR7）浸润肿瘤可预测晚期结直肠癌患者的良好预后。
Clin Cancer Res. 2012 Feb 1;18(3):850-7. doi: 10.1158/1078-0432.CCR-10-3186. Epub 2011 Dec 5.
2
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer.肿瘤相关巨噬细胞（TAM）与结直肠癌中的炎症
Cancer Microenviron. 2011 Aug;4(2):141-54. doi: 10.1007/s12307-010-0052-5. Epub 2010 Sep 17.
3
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer.
联合策略以最大化癌症免疫疗法的益处。
J Hematol Oncol. 2021 Sep 27;14(1):156. doi: 10.1186/s13045-021-01164-5.
4
Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer Prognosis.调节性 T 细胞相关通路的遗传变异与结直肠癌预后。
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2719-2728. doi: 10.1158/1055-9965.EPI-20-0714. Epub 2020 Oct 2.
5
The Role of CCL21/CCR7 Chemokine Axis in Breast Cancer Progression.CCL21/CCR7趋化因子轴在乳腺癌进展中的作用
Cancers (Basel). 2020 Apr 23;12(4):1036. doi: 10.3390/cancers12041036.
6
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.转移性结直肠癌患者的GOLFIG化疗免疫疗法。长期随访的批判性综述。
Front Oncol. 2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. eCollection 2019.
7
Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.维生素 D 可控制乳腺癌肿瘤生长和 CD8+T 细胞浸润。
Front Immunol. 2019 Jun 6;10:1307. doi: 10.3389/fimmu.2019.01307. eCollection 2019.
8
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy.趋化因子及其受体：癌症免疫治疗的新靶点。
Front Immunol. 2019 Mar 6;10:379. doi: 10.3389/fimmu.2019.00379. eCollection 2019.
9
Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile.结直肠癌浸润 T 淋巴细胞表现出独特的趋化因子受体表达谱。
Eur J Med Res. 2017 Oct 11;22(1):40. doi: 10.1186/s40001-017-0283-8.
10
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.表达FoxP3、CCR7或PD-1的肿瘤浸润性T淋巴细胞可预测生化复发后接受挽救性放疗的前列腺癌患者的预后。
Cancer Biol Ther. 2016 Nov;17(11):1213-1220. doi: 10.1080/15384047.2016.1235666.
FOXP3+ 调节性 T 细胞浸润人类癌中的预后作用：结直肠癌的矛盾。
Cancer Immunol Immunother. 2011 Jul;60(7):909-18. doi: 10.1007/s00262-011-1046-y. Epub 2011 Jun 5.
4
Immune parameters affecting the efficacy of chemotherapeutic regimens.影响化疗方案疗效的免疫参数。
Nat Rev Clin Oncol. 2011 Mar;8(3):151-60. doi: 10.1038/nrclinonc.2010.223.
5
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.调节性（FoxP3+）T 细胞肿瘤浸润是接受化疗或化疗免疫治疗的晚期结肠癌患者的有利预后因素。
J Immunother. 2010 May;33(4):435-41. doi: 10.1097/CJI.0b013e3181d32f01.
6
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.转化生长因子-β对肿瘤相关中性粒细胞表型的极化作用：“N1”与“N2”肿瘤相关中性粒细胞
Cancer Cell. 2009 Sep 8;16(3):183-94. doi: 10.1016/j.ccr.2009.06.017.
7
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.肿瘤浸润性FOXP3 + T调节细胞在结直肠癌中显示出很强的预后意义。
J Clin Oncol. 2009 Jan 10;27(2):186-92. doi: 10.1200/JCO.2008.18.7229. Epub 2008 Dec 8.
8
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).接受吉西他滨+FOLFOX化疗免疫治疗后皮下注射粒细胞巨噬细胞集落刺激因子和白细胞介素-2的结肠癌患者的免疫反馈及临床结局（GOLFIG-1试验）
Clin Cancer Res. 2008 Jul 1;14(13):4192-9. doi: 10.1158/1078-0432.CCR-07-5278.